The first half of July brought an explosion of venture capital fireworks with several $100m-plus financings for biopharmaceutical companies, but the pace of mega-round announcements has fizzled out in the second half of July with just two such deals, including Third Arc Bio Inc.’s $165m series A round.
The other late July mega-round was a $100m series C round for Autobahn Therapeutics. (Also see "Autobahn Speeds...